OTLK — Outlook Therapeutics Share News
0.000.00%
Last trade - 00:00- $126.42m
- $133.41m
- $1.41m
Brief: Outlook Therapeutics® Announces Acceptance Of Biologics License Application By U.S. FDA
Brief: Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock
Outlook Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Outlook Therapeutics Reports Financial Results For First Quarter Of 2025
Outlook Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Outlook Therapeutics Inc - Enters Securities Purchase Agreement With Avondale Capital
Brief: Outlook Therapeutics Reports Financial Results For FY 2024 And Provides Corporate Update
Outlook Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Outlook Therapeutics Inc - Approves Workforce Reduction To Cut Costs
Brief: Outlook Therapeutics Streamlines Operations
Brief: Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Brief: Outlook Therapeutics® Announces Executive Leadership Transition
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems
Outlook Therapeutics slumps as eye disease drug fails to meet key goal in study
Brief: Outlook Therapeutics Announces Preliminary Topline Results Of Norse Eight Clinical Trial
Brief: Outlook Therapeutics Announces Completion Of Enrollment In Norse Eight Clinical Trial
U.S. RESEARCH ROUNDUP-Adapthealth, Carnival, Phunware